{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:09:58Z","timestamp":1791155398900,"version":"4.1.0"},"reference-count":60,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,7,1]]},"abstract":"<jats:p>PURPOSE: To assess the toxicity and activity of oral thalidomide in Kaposi\u2019s sarcoma (KS) in a phase II dose-escalation study.<\/jats:p><jats:p>PATIENTS AND METHODS: Human immunodeficiency virus (HIV)\u2013seropositive patients with biopsy-confirmed KS that progressed over the 2 months before enrollment received an initial dose of 200 mg\/d of oral thalidomide in a phase II study. The dose was increased to a maximum of 1,000 mg\/d for up to 1 year. Anti-HIV therapy was maintained during the study period. Toxicity, tumor response, immunologic and angiogenic factors, and virologic parameters were assessed.<\/jats:p><jats:p>RESULTS: Twenty patients aged 29 to 49 years with a median CD4 count of 246 cells\/mm<jats:sup>3<\/jats:sup>(range, 14 to 646 cells\/mm<jats:sup>3<\/jats:sup>) were enrolled. All patients were assessable for toxicity, and 17 for response. Drowsiness in nine and depression in seven patients were the most frequent toxicities observed. Eight (47%; 95% confidence interval [CI], 23% to 72%) of the 17 assessable patients achieved a partial response, and an additional two patients had stable disease. Based on all 20 patients treated, the response rate was 40% (95% CI, 19% to 64%). The median thalidomide dose at the time of response was 500 mg\/d (range, 400 to 1,000 mg\/d). The median duration of drug treatment was 6.3 months, and the median time to progression was 7.3 months.<\/jats:p><jats:p>CONCLUSION: Oral thalidomide was tolerated in this population at doses up to 1,000 mg\/d for as long as 12 months and was found to induce clinically meaningful anti-KS responses in a sizable subset of the patients. Additional studies of this agent in KS are warranted.<\/jats:p>","DOI":"10.1200\/jco.2000.18.13.2593","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T09:08:21Z","timestamp":1487927301000},"page":"2593-2602","source":"Crossref","is-referenced-by-count":230,"title":["Activity of Thalidomide in AIDS-Related Kaposi\u2019s Sarcoma"],"prefix":"10.1200","volume":"18","author":[{"given":"Richard F.","family":"Little","sequence":"first","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Wyvill","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Pluda","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri","family":"Welles","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"Marshall","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fonda M.","family":"Newcomb","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Tosato","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Feigal","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Whitby","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Goedert","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[{"name":"From the HIV and AIDS Malignancy BranchMedicine Branch, and Biostatistics and Data Management Section, Division of Clinical Sciences; Division of Cancer Treatment and Diagnosis; Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute; Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda; Science Applications International Corporation, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0340","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(81)80010-2"},{"key":"R2-0340","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70382-8"},{"key":"R3-0340","doi-asserted-by":"publisher","DOI":"10.1378\/chest.91.1.39"},{"key":"R4-0340","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199509000-00008"},{"key":"R5-0340","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.653"},{"key":"R6-0340","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.914"},{"key":"R7-0340","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2353"},{"key":"R8-0340","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92654-2"},{"key":"R10-0340","unstructured":"Rutgers JL, Wieczorek R, Bonetti F, et al: The expression of endothelial cell surface antigens by AIDS-associated Kaposi\u2019s sarcoma: Evidence for a vascular endothelial cell origin. Am J Pathol 122:493,1986-499,"},{"key":"R11-0340","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704033361403"},{"key":"R12-0340","doi-asserted-by":"publisher","DOI":"10.1126\/science.2643161"},{"key":"R13-0340","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.11.4068"},{"key":"R14-0340","doi-asserted-by":"crossref","unstructured":"Nakamura S, Murakami-Mori K, Rao N, et al: Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi\u2019s sarcoma-derived spindle cells. J Immunol 158:4992,1997-5001,","DOI":"10.4049\/jimmunol.158.10.4992"},{"key":"R15-0340","unstructured":"Samaniego F, Markham PD, Gendelman R, et al: Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi\u2019s sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 152:1433,1998-1443,"},{"key":"R16-0340","doi-asserted-by":"publisher","DOI":"10.1038\/371674a0"},{"key":"R17-0340","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5241.1500"},{"key":"R18-0340","doi-asserted-by":"publisher","DOI":"10.1126\/science.7997879"},{"key":"R19-0340","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505043321802"},{"key":"R20-0340","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505043321801"},{"key":"R21-0340","doi-asserted-by":"publisher","DOI":"10.1038\/nm1295-1274"},{"key":"R22-0340","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1739"},{"key":"R23-0340","doi-asserted-by":"publisher","DOI":"10.1038\/34193"},{"key":"R24-0340","doi-asserted-by":"publisher","DOI":"10.1038\/nm0397-287"},{"key":"R25-0340","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5336.290"},{"key":"R26-0340","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"R27-0340","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00046-X"},{"key":"R28-0340","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705223362103"},{"key":"R30-0340","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.9.3085"},{"key":"R31-0340","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1201"},{"key":"R32-0340","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1112"},{"key":"R33-0340","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R35-0340","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-2670(96)00494-1"},{"key":"R36-0340","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"R37-0340","doi-asserted-by":"publisher","DOI":"10.2307\/2531294"},{"key":"R39-0340","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1998.tb02362.x"},{"key":"R40-0340","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02563.x"},{"key":"R41-0340","doi-asserted-by":"crossref","unstructured":"Jones PD, Shelley L, Wakefield D: Tumor necrosis factor-alpha in advanced HIV infection in the absence of AIDS-related secondary infections. J Acquir Immune Defic Syndr 5:1266,1992-1271,","DOI":"10.1097\/00126334-199212000-00010"},{"key":"R42-0340","doi-asserted-by":"crossref","unstructured":"Honda M, Kitamura K, Mizutani Y, et al: Quantitative analysis of serum IL-6 and its correlation with increased levels of serum IL-2R in HIV-induced diseases. J Immunol 145:4059,1990-4064,","DOI":"10.4049\/jimmunol.145.12.4059"},{"key":"R43-0340","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.19.1585"},{"key":"R44-0340","doi-asserted-by":"publisher","DOI":"10.1177\/030089169608200412"},{"key":"R46-0340","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1444"},{"key":"R48-0340","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-5-744"},{"key":"R49-0340","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860415)57:8+<1657::AID-CNCR2820571304>3.0.CO;2-N"},{"key":"R50-0340","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.1966"},{"key":"R51-0340","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)63726-9"},{"key":"R53-0340","doi-asserted-by":"crossref","unstructured":"Pearson JM, Vedagiri M: Treatment of moderately severe erythema nodosum leprosum with thalidomide: A double-blind controlled trial. Lepr Rev 40:111,1969-116,","DOI":"10.5935\/0305-7518.19690022"},{"key":"R54-0340","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1997.13.301"},{"key":"R55-0340","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1997.13.857"},{"key":"R56-0340","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.3.699"},{"key":"R57-0340","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.13.5974"},{"key":"R58-0340","doi-asserted-by":"crossref","unstructured":"McHugh SM, Rifkin IR, Deighton J, et al: The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160,1995-167,","DOI":"10.1111\/j.1365-2249.1995.tb05527.x"},{"key":"R59-0340","doi-asserted-by":"publisher","DOI":"10.1089\/088922299310269"},{"key":"R60-0340","doi-asserted-by":"crossref","unstructured":"Samaniego F, Markham PD, Gendelman R, et al: Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi\u2019s sarcoma-like lesions in nude mice. J Immunol 158:1887,1997-1894,","DOI":"10.4049\/jimmunol.158.4.1887"},{"key":"R61-0340","doi-asserted-by":"publisher","DOI":"10.1038\/345084a0"},{"key":"R62-0340","doi-asserted-by":"publisher","DOI":"10.1258\/0956462981921512"},{"key":"R63-0340","unstructured":"Fine HA, Loeffler JS, Kyritsis A, et al: A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas. Proc Am Soc Clin Oncol 16:385a,1997 (abstr 1372)"},{"key":"R64-0340","unstructured":"Figg WD, Bergan R, Brawley O, et al: Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 16:333a,1997 (abstr 1189)"},{"key":"R65-0340","doi-asserted-by":"publisher","DOI":"10.1021\/js980172i"},{"key":"R66-0340","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.3.501"},{"key":"R67-0340","unstructured":"Politi P, Reboredo G, Losso M, et al: Phase I trial of thalidomide (T) in AIDS-related Kaposi sarcoma (KS). Proc Am Soc Clin Oncol 17:41a,1998 (abstr 161)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.13.2593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:35:20Z","timestamp":1692700520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.13.2593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7,1]]},"references-count":60,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2000,7,1]]}},"alternative-id":["10.1200\/JCO.2000.18.13.2593"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.13.2593","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7,1]]}}}